---
layout: post
title: "新冠特效药板块大涨 多只个股涨停！产业链相关概念股名单来了"
date: 2022-02-15 00:37:27 +0800
categories: emnews
tags: 东财滚动新闻
---
> 2月14日，新冠药概念股走强，博腾股份、雅本化学、精华制药、森萱医药、尖峰集团等多只股票涨停，凯莱英、海特生物等涨幅居前。（中国证券报）

<!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>2月14日，新冠药概念股走强，<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span id="stock_0.300261"><a href="http://quote.eastmoney.com/unify/r/0.300261" class="keytip" data-code="0,300261">雅本化学</a></span><span id="quote_0.300261"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>、森萱医药、<span id="stock_1.600668"><a href="http://quote.eastmoney.com/unify/r/1.600668" class="keytip" data-code="1,600668">尖峰集团</a></span><span id="quote_1.600668"></span>等多只股票涨停，<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_0.300683"><a href="http://quote.eastmoney.com/unify/r/0.300683" class="keytip" data-code="0,300683">海特生物</a></span><span id="quote_0.300683"></span>等涨幅居前。</p><center><img src="https://dfscdn.dfcfw.com/download/D24680602594964732719_w943h509.jpg" alt="Image" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p style="text-align:center;">来源：choice</p><p>消息面上，国家药监局2月11日附条件批准<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装(即Paxlovid)进口注册。</p><p>民生<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>称，国内与新冠病毒治疗相关的需求未来会逐步得到释放，同时关注防疫措施解除后，相关医疗需求的恢复性增长。</p><p>Paxlovid是由PF-07321332和利托那韦合用的一种治疗方法。民生<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>认为，Paxlovid的国内获批进一步拓展目标群体，国产新冠药突破在即，有望带动API(活性药物成分)产业链进一步受益。</p><p>中国<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>报·中证金牛座记者对<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>新冠药上游产业链相关公司进行了梳理：</p><p><strong>合成PF的卡龙酸酐的国内生产企业</strong>：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300261" class="em_stock_key_common" data-code="0,300261">雅本化学</span>和<span web="1" href="http://quote.eastmoney.com/unify/r/1.600668" class="em_stock_key_common" data-code="1,600668">尖峰集团</span>。其中，<span web="1" href="http://quote.eastmoney.com/unify/r/0.300261" class="em_stock_key_common" data-code="0,300261">雅本化学</span>1月5日称，卡龙酸酐及其衍生产品产能合计约20吨/月，近期产能利用率为70%-80%。</p><p><strong>合成PF的中间体异戊烯醇的国内生产企业</strong>：<span id="stock_0.002001"><a href="http://quote.eastmoney.com/unify/r/0.002001" class="keytip" data-code="0,002001">新和成</a></span><span id="quote_0.002001"></span>和<span id="stock_1.600216"><a href="http://quote.eastmoney.com/unify/r/1.600216" class="keytip" data-code="1,600216">浙江医药</a></span><span id="quote_1.600216"></span>。产能方面，<span web="1" href="http://quote.eastmoney.com/unify/r/0.002001" class="em_stock_key_common" data-code="0,002001">新和成</span>此前在互动平台上称，公司异戊烯醇年产出约1万吨。<span id="stock_1.601995"><a href="http://quote.eastmoney.com/unify/r/1.601995" class="keytip" data-code="1,601995">中金公司</a></span><span id="quote_1.601995"></span><span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>显示，<span web="1" href="http://quote.eastmoney.com/unify/r/1.600216" class="em_stock_key_common" data-code="1,600216">浙江医药</span>异戊烯醇产能达千吨级规模。</p><p><strong>合成PF的中间体菊酸的国内生产企业</strong>：<span id="stock_1.600486"><a href="http://quote.eastmoney.com/unify/r/1.600486" class="keytip" data-code="1,600486">扬农化工</a></span><span id="quote_1.600486"></span>。</p><p><strong>利托那韦/利托那韦中间体国内生产企业</strong>：<span web="1" href="http://quote.eastmoney.com/unify/r/0.002349" class="em_stock_key_common" data-code="0,002349">精华制药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300683" class="em_stock_key_common" data-code="0,300683">海特生物</span>、歌礼制药、<span id="stock_0.000597"><a href="http://quote.eastmoney.com/unify/r/0.000597" class="keytip" data-code="0,000597">东北制药</a></span><span id="quote_0.000597"></span>。<span web="1" href="http://quote.eastmoney.com/unify/r/0.002349" class="em_stock_key_common" data-code="0,002349">精华制药</span>称，子公司森萱医药利托那韦中间体产能230吨，无原料药产能，目前具体市场占有率数据没有权威调查结果；<span web="1" href="http://quote.eastmoney.com/unify/r/0.300683" class="em_stock_key_common" data-code="0,300683">海特生物</span>在互动平台上称，子公司厦门蔚嘉主要进行利托那韦、洛匹那韦等关键中间体的生产、销售；歌礼制药称，利托那韦口服片剂产能扩大至1亿片/年；<span web="1" href="http://quote.eastmoney.com/unify/r/0.000597" class="em_stock_key_common" data-code="0,000597">东北制药</span>此前称，公司目前拥有利托那韦的制备方法专利，目前该产品尚处于研发早期阶段，能否达到申请注册阶段存在不确定性。</p><p><strong>CDMO:</strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span id="stock_1.688550"><a href="http://quote.eastmoney.com/unify/r/1.688550" class="keytip" data-code="1,688550">瑞联新材</a></span><span id="quote_1.688550"></span>。<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>2021年先后签订日常经营重大<span id="Info.3300"><a href="http://data.eastmoney.com/zdht/" class="infokey">合同</a></span>，金额为4.81亿美元和27.2亿元人民币；<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>日前<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>，收到<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>旗下公司6.81亿美元采购订单；<span web="1" href="http://quote.eastmoney.com/unify/r/1.688550" class="em_stock_key_common" data-code="1,688550">瑞联新材</span>2021年半年报显示，供应给辉瑞公司的某医药中间体产品对应终端药物的适应症为COVID-19项目，该终端药物的临床进展无法获知。</p><center><img src="https://dfscdn.dfcfw.com/download/D25365022256600830245_w781h625.jpg" alt="Image" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p style="text-align:center;">来源：中证金牛座记者整理</p><p>民生证券称，国产口服新冠药的上市及稳定供应有望带动上游原料药产业链景气度提升。目前国内进入3期临床的有真实生物的阿兹夫定和<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>的核苷类VV116，VV116是全球第三款和国产首个获紧急使用授权的口服新冠药，未来在国内获批上市的可能性较大，与辉瑞同机理的其他国产药物目前均处于临床前状态。此外新冠治疗仍会带动很多周边需求，如激素等对症治疗药物的应用。</p><center><img src="https://dfscdn.dfcfw.com/download/D25105282982826951878_w463h132.jpg" width="463" emheight="132" orginial_src="https://dfscdn.dfcfw.com/download/D25105282982826951878_w463h132_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p style="text-align:center;">来源：民生证券研报</p><h3 class="emh3">之前报道</h3><p><a href="https://finance.eastmoney.com/a/202202142274930141.html">辉瑞新冠口服药附条件获批 概念股获机构集中关注 4股净利润有望翻倍</a><br /></p><p><a href="https://finance.eastmoney.com/a/202202132274909110.html">关注！辉瑞新冠口服药国内获批 这些A股公司已提前布局</a><br /></p><p><a href="https://finance.eastmoney.com/a/202202122274771510.html">辉瑞新冠口服药要来了 原料和中间体企业迎来风口？</a></p><p class="em_media">（文章来源：中国证券报）</p>

<http://stock.eastmoney.com/news/1406,202202142276048365.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)